Local biotech invests in erectile dysfunction drug

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

Pacific Therapeutics (CNSX:PT) is planning to move into the lucrative erectile dysfunction treatment market. 

The company – which specializes in repurposing drugs already approved for other purposes – has signed a letter of intent to license a sublingual formation for drugs used to treat erectile dysfunction. Sublingual formations (which allow drugs to be dissolved under the tongue) absorb more quickly and therefore take effect sooner.

"We expect to move this product through pivotal trials and through regulatory approval over the next year and intend to begin marketing within two years," said Pacific Therapeutics CEO Douglas Unwin.

"We expect to complete the license in the first quarter of 2013, and move rapidly to the late-stage clinical trials and marketing."

In 2006, the market for drugs for treating erectile dysfunction exceeded $3 billion, the company said.

Pacific Therapeutics has two other drugs in the pipeline, both of which are for the treatment of scarring of human tissue.

Its lead product, PTL-202, is a combination of drugs being tested for efficacy in treating idiopathic pulmonary fibrosis, a progressive scarring of the lungs. The drug is already approved by the Food and Drug Administration in the U.S. and is currently in stage one of clinical trials.

nbennett@biv.com

@nbennett_biv

comments powered by Disqus

More from Technology

Pokemon Go phenomenon accelerates local push for ‘digital lifestyles’

Vancouver tech companies benefitting from high-profile Pokemon game

Read Article

Nursing shortages spurs former video game developers into action

New app and virtual reality help health authorities train up new nurses amidst shortages

Read Article

U.S. military to test SFU-invented bionic exoskeletons

Bionic Power to help soldiers lighten load of carrying batteries

Read Article

B.C. firm lands Microsoft HoloLens program, ushers in augmented revenue reality

Finger Food Studios one of just eight global agencies — and the only one in Canada — selected for Microsoft’s augmented reality project

Read Article

BIV on Global BC July 15, 2016: Microsoft HoloLens, Canadian retail sales

Read Article

Subscribe to our mailing lists

* indicates required

Newsletters

* You can modify your newsletter subscriptions at the bottom of any newsletter you receive.
×